EyeGate lands $15M in third round

With the help of Medicis Capital, Ventech, Innoven Partenaires and The Nexus Group, Eyegate has landed $15 million in a third round of venture funding. According to EyeGate President and CEO Stephen From, the company will use the funding to commence two Phase II clinical studies using the EyeGate II Delivery System and it's own formulation of a corticosteroid. Eyegate will study the drug for severe uveitis in the first half of 2008, and a second trial for dry eye will start later this year. To date, the company has raised  $31 million in funding.

- here's the release for more

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.